Pieris Pharmaceuticals Announces Merger and Share Increase

Written by Emily J. Thompson, Senior Investment Analyst

PIRS%

Source: Business Insider

Updated: Dec 12 2024

0mins

Source: Business Insider

Pieris Pharmaceuticals Announcement: Pieris Pharmaceuticals has approved a significant increase in authorized shares and the 2024 Equity Incentive Plan during a special stockholder meeting, alongside finalizing a merger with Palvella Therapeutics which will lead to a name change.
Company Overview: Operating in the biotechnology sector, Pieris focuses on developing therapeutic proteins, currently holds a market cap of $21.92M, and has a year-to-date price performance of 14.01%.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Pieris Pharmaceuticals Announces Merger and Share Increase

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Trump Administration Requires Tech Firms to Fund $15B Power Generation Plan

IonQ Advances in Quantum Computing with Over $68 Million Revenue in 2025

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch